Non-small cell lung cancer (NSCLC)
Conditions
Brief summary
To assess the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival (PFS) at 12 months according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Detailed description
"1. To evaluate the ORR of the treatment as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1.", 2. To evaluate the PFS rate at 24 months of the treatment., 3. To evaluate the Overall survival (OS) rate at 12 and 24 months of the treatment., 4. To evaluate the sites of first failure, 5. To evaluate the safety and tolerability of Atezolizumab in combination with chemotherapy and Atezolizumab as maintenance treatment.
Interventions
DRUGTecentriq 1 200 mg concentrate for solution for infusion
Sponsors
Fundacion GECP
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival (PFS) at 12 months according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. | — |
Secondary
| Measure | Time frame |
|---|---|
| "1. To evaluate the ORR of the treatment as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1.", 2. To evaluate the PFS rate at 24 months of the treatment., 3. To evaluate the Overall survival (OS) rate at 12 and 24 months of the treatment., 4. To evaluate the sites of first failure, 5. To evaluate the safety and tolerability of Atezolizumab in combination with chemotherapy and Atezolizumab as maintenance treatment. | — |
Countries
Spain
Outcome results
None listed